Breaking News

Evolent Health price target lowered to $20 from $32 at KeyBanc. KeyBanc analyst Donald Hooker lowered his price target for Evolent Health to $20 from $32, while reiterating an Overweight rating on the shares after its largest client, Passport Health Plan, announced cost cuts that should save it from imminent insolvency. The cost reductions appear to include a cut in fees to Evolent Health and lowered reimbursement to its provider network, he notes.

Evolent Health price target lowered to $21.50 from $34 at Wells Fargo. Wells Fargo analyst Jamie Stockton lowered his price target for Evolent Health to $21.50 from $34 as it reported a mixed December quarter with revenue of $193M versus the $189M consensus. The real story is 2019 guidance, though, with the company basically guiding for -3% organic revenue growth, he contends. Stockton believes the business is going through a difficult period, but believes healthy growth can resume in 2020. He reiterates an Outperform rating on the shares.

Evolent Health price target lowered to $21 form $31 at Oppenheimer. Oppenheimer analyst Mohan Naidu lowered his price target for Evolent Health to $21 from $31 as he believes the company's CY19 guidance will pressure the stock in the near-term as investors process the various moving parts that caused numbers uncertainty. While the revenue weakness is disappointing, Evolent Health essentially trimmed off the riskiest portion to improve the quality of numbers going forward, he contends. The analyst reiterates an Outperform rating on the shares.

Canaccord says Evolent Health guidance worse than feared, lowers target to $19. Canaccord analyst Richard Close believes the rough ride for Evolent Health investors could be coming to an end as the company maneuvers through a challenging first half of 2019. The analyst noted the company's guidance was much worse than anticipated, but he views the first half 2019 headwinds as short-term in nature. With management exuding confidence in the business model, he sees attractive long-term returns. Close maintained his Buy rating and lowered his price target to $19 from $25 on Evolent Health shares.

Evolent Health selloff today brings attractive entry point, says Citi. Citi analyst Stephanie Demko believes today's post-earnings selloff in shares of Evolent Health brings an attractive entry point. While the company will face a number of headwinds in the first half of 2019, the stock correction is overblown, Demko tells investors in a research note. She lowered her price target for Evolent Health to $25 from $32 to reflect the "disappointing results" and reiterates a Buy rating on the shares.

Evolent Health price target lowered to $20 from $37 at Cantor Fitzgerald. Cantor Fitzgerald analyst Steven Halper lowered his price target for Evolent Health to $20 citing the company's "disappointing" 2019 outlook. The company indicated that the first half of 2019 will likely be affected by "a wind-down of a few health plans" and lower than expected growth from newly launched Medicaid plans in Florida, Halper tells investors in a post-earnings research note. The analyst, however, says his long-term investment thesis for Evolent shares remains intact, "given the ongoing shift to value-based reimbursement." He reiterates an Overweight rating on the name.

Evolent Health now a 'plug your nose and buy it' stock, says Piper Jaffray. Trading at one times enterprise value to estimate 2019 revenue, Evolent Health is now a "plug your nose and buy it" stock, Piper Jaffray analyst Sean Wieland tells investors in a research note. The analyst lowered his price target for the shares to $19 from $33 and maintains an Overweight rating on the name. With many moving parts in the 2019 guidance, there are "plenty of reasons to be skeptical, including the still outstanding issue of the financial viability of Passport," says the analyst. However, the analyst believes value-based care "will come...eventually." Evolent remains the only derivative play on value-based care, Wieland says.